J F Kocsis1, G Llanos, E Holmer
1Cordis, a Johnson & Johnson Company, Warren, NJ 07059, USA.
Heparin-coated stents, featuring the Carmeda BioActive Surface (CBAS), were developed to reduce stent thrombosis and bleeding complications. Studies evaluated their preclinical thromboresistance and clinical effectiveness in interventional cardiology.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: